Skip to main content

ACoP 2024 Main banner

Conference Program

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Nassim Djebli, PharmD, PhD

Executive Director, Clinical Pharmacometrics
Luzsana Biotechnology

Poster(s):

(W-049) Exposure-Response Analysis for Hepatotoxicity of Rivoceranib Monotherapy and in Combination with Camrelizumab in Patients with Various Cancers, Including Advanced Hepatocellular Carcinoma

Wednesday, November 13, 2024
7:00 AM – 1:45 PM MST